{"id":"NCT02796677","sponsor":"AstraZeneca","briefTitle":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","officialTitle":"A 24 Week Treatment, Multicenter, Randomized, Double Blinded, Double Dummy, Parallel-group, Clinical Trial Evaluating the Efficacy and Safety of Aclidinium Bromide 400 μg/Formoterol Fumarate 12 μg Fixed-dose Combination BID Compared With Each Monotherapy (Aclidinium Bromide 400 μg BID and Formoterol Fumarate 12 μg BID) and Tiotropium 18 μg QD When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-05","primaryCompletion":"2017-06-08","completion":"2017-06-08","firstPosted":"2016-06-13","resultsPosted":"2018-11-09","lastUpdate":"2018-11-09"},"enrollment":1595,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)","otherNames":["Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)"]},{"type":"DRUG","name":"Aclidinium bromide 400 μg (AB 400 μg)","otherNames":["Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)"]},{"type":"DRUG","name":"Formoterol fumarate 12 μg (FF 12 μg)","otherNames":["Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)"]},{"type":"OTHER","name":"Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg","otherNames":["Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)"]},{"type":"DRUG","name":"Tiotropium 18 μg (TIO 18 μg)","otherNames":["Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)"]},{"type":"OTHER","name":"Placebo to TIO 18 μg","otherNames":["Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)"]}],"arms":[{"label":"AB/FF 400/12 μg BID","type":"EXPERIMENTAL"},{"label":"AB 400 μg BID","type":"EXPERIMENTAL"},{"label":"FF 12 μg BID","type":"EXPERIMENTAL"},{"label":"TIO 18 μg QD","type":"EXPERIMENTAL"}],"summary":"This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).","primaryOutcome":{"measure":"Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24","timeFrame":"At baseline 1-hour postdose and Week 24","effectByArm":[{"arm":"AB/FF 400/12 μg","deltaMin":0.253,"sd":0.013},{"arm":"AB 400 μg","deltaMin":0.169,"sd":0.011},{"arm":"FF 12 μg","deltaMin":0.168,"sd":0.013},{"arm":"TIO 18 μg","deltaMin":0.161,"sd":0.011}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":23},"locations":{"siteCount":163,"countries":["United States","Bulgaria","Czechia","Germany","Hungary","Israel","Poland","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["30962681"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4098&filename=D6571C00001-Protocol-Final-redacted-06Jun2018(PdfA).pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4098&filename=D6571C00001-SAP-Amendment-1-Final-redacted-06Jun2018(PdfA).pdf"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":314},"commonTop":["Chronic obstructive pulmonary","Nasopharyngitis","Headache","Upper respiratory tract infection","Dyspnoea"]}}